Correction: Grant of Warrants
12/06/2023 18:15
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230612:nRSL4631Ca&default-theme=true
RNS Number : 4631C Cellular Goods PLC 12 June 2023
The information contained within this announcement is deemed by the Company to
constitute inside information stipulated under the Market Abuse Regulation
(EU) No. 596/2014, as retained as part of the law of England and Wales.
Upon the publication of this announcement via the Regulatory Information
Service, this inside information is now considered to be in the public domain.
Press release
12 June 2023
Cellular Goods PLC
("Cellular Goods" or "the Company")
Correction: Grant of Warrants
The following amendment has been made to the 'Grant of Warrants' announcement
released on 9 June 2023 at 07:00 a.m. under RNS number 1766C. The description
of the total number of Warrants in issue was incomplete, which has been
corrected in the revised text below.
Cellular Goods (LSE: CBX) a UK-based skincare and wellness company providing
premium consumer products formulated with lab-produced cannabinoids, announces
that it has granted a total of 3,000,000 warrants to subscribe for new
ordinary shares of £0.001 each ("Warrants") to members of its Advisory Board.
The Warrants are exercisable at 1.5 pence per ordinary share.
One third of the warrants will vest on 8 June 2024 with the remaining two
thirds vesting in 24 equal monthly instalments thereafter. The Warrants have
an exercise period from the date of grant to 8 June 2028.
Following the issue of the Warrants, the Company has a total of:
· 12,500,000 warrants in issue to staff and founders at exercise prices between
5 pence and 8.13 pence per ordinary share;
· 4,000,000 granted to the Company's non-executive directors at exercise prices
between 0.97 pence and 2.9 pence per ordinary share;
· 5,000,000 at an exercise price of 0.97 pence per ordinary share to Matthew
Lodge in connection with the King Tide acquisition;
· 3,000,000 to the Advisory Board, details of which are set out in the
announcement; and
· 12,960,000 to brokers at an exercise price of 5 pence per ordinary share in
connection with the Company's IPO.
In addition, under the Company's share option plan, options over in aggregate
24,331,594 ordinary shares at exercise prices between 1.2 pence and 7.812
pence per ordinary share remain exercisable.
For further information please contact:
Cellular Goods
Darcy Taylor via Tancredi +44 207 887 7633
Chairman and interim CEO
Neil Thapar +44 787 645 5323
Investor Relations
First Sentinel Corporate Finance
Corporate Broker & Advisor
Brian Stockbridge +44 7876 888 011
Novum Securities
Corporate Broker
Colin Rowbury
Jon Belliss +44 207 399 9427
Tancredi Intelligent Communication
Media Relations
Helen Humphrey +44 744 922 6720
Charlie Hobbs +44 789 755 7112
cellulargoods@tancredigroup.com (mailto:cellulargoods@tancredigroup.com)
About Cellular Goods PLC:
Cellular Goods develops and markets premium quality skincare and wellness
products based on proprietary formulations incorporating biosynthetic lab-made
cannabinoids. Our branded products are efficacy-led and research-backed and
available online in the UK and US. The Company is incorporated in the UK and
listed on the Main Market of the London Stock Exchange. For more information,
visit www.cellular-goods.com (http://www.cellular-goods.com) .
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END IOEGZGMVNZMGFZM